Botulism MedWatch alert

Executive Summary

FDA issues a MedWatch alert due to reports of adverse events and death following the use of botulinum toxins Feb. 8. The early communication about an ongoing safety review of Allergan's Botox and Botox Cosmetic (type A) and Solstice Neurosciences' Myobloc (type B) cites adverse events for both FDA-approved and unapproved uses. The events are "suggestive of botulism," the alert states, and advises health care professionals to be alert for potency differences among botulinum products and signs and symptoms of systemic effects of treatment...